HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis

NASDAQ:HBIO • US4169061052

0.5861 USD
-0.01 (-1.16%)
At close: Feb 19, 2026
0.5701 USD
-0.02 (-2.73%)
After Hours: 2/19/2026, 4:03:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

HBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. HBIO may be in some trouble as it scores bad on both profitability and health. HBIO is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year HBIO was profitable.
  • HBIO had a positive operating cash flow in the past year.
  • In the past 5 years HBIO always reported negative net income.
  • HBIO had a positive operating cash flow in each of the past 5 years.
HBIO Yearly Net Income VS EBIT VS OCF VS FCFHBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -69.03%, HBIO is doing worse than 89.66% of the companies in the same industry.
  • HBIO has a worse Return On Equity (-382.68%) than 87.93% of its industry peers.
Industry RankSector Rank
ROA -69.03%
ROE -382.68%
ROIC N/A
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
HBIO Yearly ROA, ROE, ROICHBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15

1.3 Margins

  • HBIO has a Gross Margin of 56.94%. This is in the better half of the industry: HBIO outperforms 72.41% of its industry peers.
  • HBIO's Gross Margin has been stable in the last couple of years.
  • HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
HBIO Yearly Profit, Operating, Gross MarginsHBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HBIO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HBIO has more shares outstanding
  • The debt/assets ratio for HBIO is higher compared to a year ago.
HBIO Yearly Shares OutstandingHBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HBIO Yearly Total Debt VS Total AssetsHBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.68, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.68, HBIO is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
  • There is no outstanding debt for HBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 4.98
Altman-Z -2.68
ROIC/WACCN/A
WACC10.6%
HBIO Yearly LT Debt VS Equity VS FCFHBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

  • HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • HBIO has a Current ratio of 0.81. This is amonst the worse of the industry: HBIO underperforms 89.66% of its industry peers.
  • HBIO has a Quick Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • HBIO has a Quick ratio of 0.41. This is amonst the worse of the industry: HBIO underperforms 93.10% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.41
HBIO Yearly Current Assets VS Current LiabilitesHBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • HBIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • The earnings per share for HBIO have been decreasing by -19.73% on average. This is quite bad
  • The Revenue for HBIO has decreased by -10.60% in the past year. This is quite bad
  • The Revenue has been decreasing by -4.12% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%

3.2 Future

  • Based on estimates for the next years, HBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 50.37% on average per year.
  • Based on estimates for the next years, HBIO will show a small growth in Revenue. The Revenue will grow by 0.97% on average per year.
EPS Next Y-49%
EPS Next 2Y27.08%
EPS Next 3Y50.37%
EPS Next 5YN/A
Revenue Next Year-8.37%
Revenue Next 2Y-0.62%
Revenue Next 3Y0.97%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HBIO Yearly Revenue VS EstimatesHBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
HBIO Yearly EPS VS EstimatesHBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.05 0.1 0.15 0.2 0.25

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 14.65, the valuation of HBIO can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 93.10% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of HBIO to the average of the S&P500 Index (27.27), we can say HBIO is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 6.05, the valuation of HBIO can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, HBIO is valued cheaper than 100.00% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.16. HBIO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 14.65
Fwd PE 6.05
HBIO Price Earnings VS Forward Price EarningsHBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HBIO is valued cheaper than 93.10% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3.84
EV/EBITDA 12.16
HBIO Per share dataHBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • HBIO's earnings are expected to grow with 50.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3Y50.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARVARD BIOSCIENCE INC

NASDAQ:HBIO (2/19/2026, 4:03:57 PM)

After market: 0.5701 -0.02 (-2.73%)

0.5861

-0.01 (-1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners48.8%
Inst Owner Change26.41%
Ins Owners3.96%
Ins Owner Change0%
Market Cap26.21M
Revenue(TTM)87.37M
Net Income(TTM)-53.84M
Analysts80
Price Target2.04 (248.06%)
Short Float %1.43%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.02%
Min EPS beat(2)-100%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-1.23%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-39.49%
EPS beat(12)5
Avg EPS beat(12)-32.85%
EPS beat(16)5
Avg EPS beat(16)-35.95%
Revenue beat(2)1
Avg Revenue beat(2)-0.39%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)2.52%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)3
Avg Revenue beat(12)-4.45%
Revenue beat(16)3
Avg Revenue beat(16)-4.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE 14.65
Fwd PE 6.05
P/S 0.3
P/FCF 3.84
P/OCF 3.07
P/B 1.86
P/tB N/A
EV/EBITDA 12.16
EPS(TTM)0.04
EY6.82%
EPS(NY)0.1
Fwd EY16.53%
FCF(TTM)0.15
FCFY26.02%
OCF(TTM)0.19
OCFY32.62%
SpS1.95
BVpS0.31
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.53
Profitability
Industry RankSector Rank
ROA -69.03%
ROE -382.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.94%
FCFM 7.81%
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 4.98
Debt/EBITDA 0
Cap/Depr 27.22%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion 193.66%
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.41
Altman-Z -2.68
F-Score4
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
EPS Next Y-49%
EPS Next 2Y27.08%
EPS Next 3Y50.37%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
Revenue Next Year-8.37%
Revenue Next 2Y-0.62%
Revenue Next 3Y0.97%
Revenue Next 5YN/A
EBIT growth 1Y63.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5166.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.1%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%

HARVARD BIOSCIENCE INC / HBIO FAQ

What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HBIO.


Can you provide the valuation status for HARVARD BIOSCIENCE INC?

ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.


Can you provide the profitability details for HARVARD BIOSCIENCE INC?

HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.


Can you provide the financial health for HBIO stock?

The financial health rating of HARVARD BIOSCIENCE INC (HBIO) is 3 / 10.